Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) EBITDA (2022 - 2025)

Historic EBITDA for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$13.4 million.

  • Pharmaceuticals' EBITDA fell 8386.21% to -$13.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$22.4 million, marking a year-over-year decrease of 14733.38%. This contributed to the annual value of $39.8 million for FY2024, which is 4549.44% up from last year.
  • As of Q2 2025, Pharmaceuticals' EBITDA stood at -$13.4 million, which was down 8386.21% from -$11.2 million recorded in Q1 2025.
  • Pharmaceuticals' EBITDA's 5-year high stood at $72.1 million during Q4 2022, with a 5-year trough of -$13.4 million in Q2 2025.
  • For the 4-year period, Pharmaceuticals' EBITDA averaged around $4.1 million, with its median value being -$7.7 million (2022).
  • As far as peak fluctuations go, Pharmaceuticals' EBITDA skyrocketed by 26744.19% in 2024, and later plummeted by 21878.71% in 2025.
  • Quarter analysis of 4 years shows Pharmaceuticals' EBITDA stood at $72.1 million in 2022, then crashed by 30.8% to $49.9 million in 2023, then crashed by 114.59% to -$7.3 million in 2024, then plummeted by 83.86% to -$13.4 million in 2025.
  • Its last three reported values are -$13.4 million in Q2 2025, -$11.2 million for Q1 2025, and -$7.3 million during Q2 2024.